{"id":"intralesional-injection-of-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Bleeding or hemorrhage"},{"rate":null,"effect":"Wound healing complications"},{"rate":null,"effect":"Systemic VEGF inhibition effects (if significant absorption)"}]},"_chembl":{"chemblId":"CHEMBL2108490","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When injected directly into a lesion, bevacizumab binds to VEGF and prevents its interaction with VEGF receptors on endothelial cells. This inhibits angiogenesis—the formation of new blood vessels that tumors depend on for growth and metastasis. The intralesional route delivers high local concentrations directly to the target tissue while minimizing systemic exposure.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting new blood vessel formation to reduce tumor vascularity and nutrient supply.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:44.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intralesional treatment of solid tumors or lesions (investigational phase 3)"}]},"trialDetails":[{"nctId":"NCT07014280","phase":"PHASE4","title":"Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2023-09-01","conditions":"Keloids","enrollment":28},{"nctId":"NCT05314673","phase":"PHASE4","title":"Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients","status":"COMPLETED","sponsor":"University Hospital Fattouma Bourguiba","startDate":"2019-01-01","conditions":"Pterygium","enrollment":60},{"nctId":"NCT02007174","phase":"","title":"Bevacizumab Injection for Recurrent Pterygium","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2012-03","conditions":"Recurrent Pterygium","enrollment":38},{"nctId":"NCT01408953","phase":"PHASE2","title":"Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue","status":"TERMINATED","sponsor":"Tirgan, Michael H., M.D.","startDate":"2012-02","conditions":"Keloid","enrollment":2},{"nctId":"NCT02555800","phase":"PHASE2","title":"Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis","status":"UNKNOWN","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2014-12","conditions":"Recurrent Respiratory Papillomatosis","enrollment":36},{"nctId":"NCT01296815","phase":"PHASE2","title":"Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity","status":"COMPLETED","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2010-09","conditions":"Kaposi´s Sarcoma","enrollment":14},{"nctId":"NCT01380678","phase":"PHASE3","title":"Intralesional Bevacizumab Injection on Primary Pterygium","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2009-01","conditions":"Pterygium, Inflammation","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin"],"phase":"phase_3","status":"active","brandName":"Intralesional injection of bevacizumab","genericName":"Intralesional injection of bevacizumab","companyName":"Khon Kaen University","companyId":"khon-kaen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting new blood vessel formation to reduce tumor vascularity and nutrient supply. Used for Intralesional treatment of solid tumors or lesions (investigational phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}